Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Weight says a lot. In the kitchen, it could mean cooking with too little or too much of an ingredient. For scientists, a ...

Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive ...

Finger-prick dried blood sampling can accurately measure key Alzheimer’s disease biomarkers, including p-tau217, GFAP, and ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

Massive endeavor including Hopkins researchers and students aims to understand the planet's most biodiverse habitats ...